Free Trial

Nektar Therapeutics (NKTR) News Today

Nektar Therapeutics logo
$0.64 -0.05 (-6.58%)
Closing price 05/6/2025 04:00 PM Eastern
Extended Trading
$0.66 +0.01 (+2.18%)
As of 05/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Nektar Therapeutics
Nektar Therapeutics stock logo
22Nw LP Takes Position in Nektar Therapeutics (NASDAQ:NKTR)
22Nw LP acquired a new position in Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 2,191,750 shares of the biopharmaceutical company's stock, valued at approximately $2,038,000. Nektar Therapeutics makes up
Nektar Therapeutics stock logo
Nektar Therapeutics (NKTR) to Release Earnings on Thursday
Nektar Therapeutics (NASDAQ:NKTR) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-nektar-therapeutics-stock/)
Nektar Therapeutics stock logo
Nantahala Capital Management LLC Acquires 3,700,000 Shares of Nektar Therapeutics (NASDAQ:NKTR)
Nantahala Capital Management LLC increased its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 90.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,810,000 shares of the biopharmaceutical
Nektar Therapeutics stock logo
Nektar Therapeutics (NASDAQ:NKTR) Receives Consensus Rating of "Buy" from Analysts
Shares of Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) have been given an average rating of "Buy" by the eight analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy
Nektar Therapeutics stock logo
Renaissance Technologies LLC Raises Stock Position in Nektar Therapeutics (NASDAQ:NKTR)
Renaissance Technologies LLC grew its position in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 17.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,910,786 shares of the biopharmaceutical company's
Nektar Therapeutics stock logo
Diadema Partners LP Acquires New Holdings in Nektar Therapeutics (NASDAQ:NKTR)
Diadema Partners LP purchased a new stake in Nektar Therapeutics (NASDAQ:NKTR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 698,919 shares of the biopharmaceutical company's stock, valued at appr
Nektar Therapeutics stock logo
Altium Capital Management LLC Raises Holdings in Nektar Therapeutics (NASDAQ:NKTR)
Altium Capital Management LLC raised its position in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 26,172.0% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,000,000 shares of the biopharmaceutical company's stock after purchasing
Nektar Therapeutics stock logo
Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated at StockNews.com
StockNews.com initiated coverage on Nektar Therapeutics in a research note on Wednesday. They issued a "hold" rating on the stock.
Nektar Therapeutics stock logo
Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by Jefferies Financial Group
Jefferies Financial Group raised Nektar Therapeutics from a "hold" rating to a "buy" rating and lifted their price target for the stock from $1.00 to $2.00 in a report on Friday.
Nektar management to meet virtually with B. Riley
Nektar upgraded to Buy from Hold at Jefferies
Nektar Therapeutics stock logo
Equities Analysts Set Expectations for NKTR Q1 Earnings
Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Stock analysts at Zacks Research upped their Q1 2025 EPS estimates for shares of Nektar Therapeutics in a report issued on Wednesday, April 2nd. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings per
Nektar Therapeutics stock logo
Q1 Earnings Estimate for NKTR Issued By Zacks Research
Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Equities researchers at Zacks Research issued their Q1 2027 earnings per share (EPS) estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Wednesday, April 2nd. Zacks Research analyst K. Das forecasts
Nektar Therapeutics stock logo
Nektar Therapeutics (NASDAQ:NKTR) Receives Average Rating of "Buy" from Brokerages
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) has earned an average rating of "Buy" from the seven analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a
Nektar Therapeutics stock logo
Traders Buy Large Volume of Call Options on Nektar Therapeutics (NASDAQ:NKTR)
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) was the recipient of unusually large options trading activity on Friday. Traders acquired 2,351 call options on the stock. This represents an increase of approximately 245% compared to the typical volume of 681 call options.
Nektar files $300M mixed securities shelf
Piper Sandler Remains a Buy on Nektar Therapeutics (NKTR)
Nektar management to meet with Piper Sandler
Nektar Therapeutics stock logo
Primecap Management Co. CA Decreases Position in Nektar Therapeutics (NASDAQ:NKTR)
Primecap Management Co. CA lowered its position in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 6.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,540,386 shares of the biopharmaceu
Nektar Therapeutics stock logo
HC Wainwright Issues Positive Estimate for NKTR Earnings
Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Equities researchers at HC Wainwright raised their Q1 2025 EPS estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Thursday, March 13th. HC Wainwright analyst A. He now anticipates that the biopharma
Nektar Therapeutics stock logo
Q1 EPS Estimate for Nektar Therapeutics Boosted by Analyst
Nektar Therapeutics (NASDAQ:NKTR - Free Report) - William Blair lifted their Q1 2025 earnings per share estimates for shares of Nektar Therapeutics in a research report issued on Thursday, March 13th. William Blair analyst A. Hsieh now forecasts that the biopharmaceutical company will earn ($0.19
Nektar Therapeutics stock logo
Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by Oppenheimer
Oppenheimer raised Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $6.00 price target on the stock in a report on Friday.
Nektar Therapeutics stock logo
William Blair Reiterates Market Perform Rating for Nektar Therapeutics (NASDAQ:NKTR)
William Blair restated a "market perform" rating on shares of Nektar Therapeutics in a research note on Thursday.
Nektar Therapeutics stock logo
Nektar Therapeutics (NASDAQ:NKTR) Given Buy Rating at HC Wainwright
HC Wainwright reaffirmed a "buy" rating and set a $6.50 price target on shares of Nektar Therapeutics in a research report on Thursday.
Q4 2024 Nektar Therapeutics Earnings Call
Nektar up 12% to 91c after Oppenheimer upgrade with $6 target
Nektar Therapeutics stock logo
Nektar Therapeutics (NASDAQ:NKTR) Releases Earnings Results, Beats Expectations By $0.33 EPS
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.33. Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%.
Nektar Therapeutics stock logo
Nektar Therapeutics (NASDAQ:NKTR) Posts Quarterly Earnings Results, Beats Estimates By $0.33 EPS
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) released its earnings results on Wednesday. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.33. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%.
Nektar reports Q4 adjusted EPS (15c), consensus (19c)
Get Nektar Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.

NKTR Media Mentions By Week

NKTR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NKTR
News Sentiment

0.35

0.69

Average
Medical
News Sentiment

NKTR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NKTR Articles
This Week

5

3

NKTR Articles
Average Week

Get Nektar Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:NKTR) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners